DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,218,455,989 | +6.7% | 4,911,060 | +3.2% | 0.80% | +12.4% |
| Q2 2023 | $1,141,577,116 | +39.7% | 4,756,487 | +46.7% | 0.71% | +31.7% |
| Q1 2023 | $817,050,290 | -10.4% | 3,241,751 | -5.7% | 0.54% | -17.3% |
| Q4 2022 | $912,184,562 | -24.6% | 3,436,720 | -63.3% | 0.65% | -28.0% |
| Q3 2022 | $1,210,315,106 | -0.4% | 9,362,102 | +95.3% | 0.90% | +8.0% |
| Q2 2022 | $1,215,465,000 | -20.9% | 4,794,256 | -8.5% | 0.84% | +12.9% |
| Q1 2022 | $1,536,380,000 | -16.2% | 5,237,720 | -6.1% | 0.74% | -3.0% |
| Q4 2021 | $1,834,283,000 | +11.2% | 5,575,139 | +2.9% | 0.76% | +6.1% |
| Q3 2021 | $1,649,085,000 | +14.9% | 5,416,873 | +1.3% | 0.72% | +17.4% |
| Q2 2021 | $1,434,675,000 | +15.4% | 5,346,103 | -3.2% | 0.61% | +8.1% |
| Q1 2021 | $1,243,049,000 | +12.6% | 5,522,584 | +11.2% | 0.57% | +10.7% |
| Q4 2020 | $1,103,691,000 | +4.4% | 4,968,395 | +1.2% | 0.51% | -6.9% |
| Q3 2020 | $1,057,534,000 | +13.8% | 4,911,263 | -6.6% | 0.55% | +5.6% |
| Q2 2020 | $929,661,000 | +29.6% | 5,257,449 | +1.5% | 0.52% | +5.7% |
| Q1 2020 | $717,094,000 | -10.3% | 5,180,810 | -0.6% | 0.49% | +20.8% |
| Q4 2019 | $799,731,000 | +19.9% | 5,210,644 | +12.8% | 0.41% | +13.3% |
| Q3 2019 | $666,939,000 | +63.3% | 4,617,834 | +61.6% | 0.36% | +62.6% |
| Q2 2019 | $408,466,000 | +316.0% | 2,858,029 | +284.3% | 0.22% | +311.1% |
| Q1 2019 | $98,185,000 | +359.7% | 743,736 | +259.1% | 0.05% | +285.7% |
| Q4 2018 | $21,357,000 | -13.2% | 207,126 | -8.5% | 0.01% | +7.7% |
| Q3 2018 | $24,593,000 | +15.3% | 226,353 | +4.7% | 0.01% | +8.3% |
| Q2 2018 | $21,329,000 | +1.7% | 216,134 | +0.9% | 0.01% | 0.0% |
| Q1 2018 | $20,979,000 | -4.1% | 214,306 | -9.1% | 0.01% | -7.7% |
| Q4 2017 | $21,879,000 | -47.6% | 235,689 | -51.6% | 0.01% | -51.9% |
| Q3 2017 | $41,744,000 | -19.0% | 486,659 | -20.3% | 0.03% | -22.9% |
| Q2 2017 | $51,534,000 | +170.8% | 610,652 | +174.4% | 0.04% | -73.9% |
| Q1 2017 | $19,032,000 | +6.7% | 222,507 | -2.8% | 0.13% | +1.5% |
| Q4 2016 | $17,837,000 | -2.1% | 229,002 | -1.5% | 0.13% | -1.5% |
| Q3 2016 | $18,225,000 | -26.2% | 232,499 | -5.0% | 0.13% | -34.6% |
| Q2 2016 | $24,705,000 | -0.5% | 244,616 | -6.5% | 0.20% | +2.0% |
| Q1 2016 | $24,821,000 | +141.7% | 261,582 | +136.6% | 0.20% | +145.1% |
| Q4 2015 | $10,268,000 | +8.8% | 110,549 | -0.2% | 0.08% | -1.2% |
| Q3 2015 | $9,440,000 | -1.5% | 110,821 | -1.1% | 0.08% | +10.7% |
| Q2 2015 | $9,587,000 | +1.6% | 112,053 | +0.8% | 0.08% | +2.7% |
| Q1 2015 | $9,438,000 | -1.5% | 111,178 | -0.6% | 0.07% | +5.8% |
| Q4 2014 | $9,582,000 | +40.8% | 111,795 | +24.9% | 0.07% | +7.8% |
| Q3 2014 | $6,804,000 | -3.4% | 89,533 | 0.0% | 0.06% | -3.0% |
| Q2 2014 | $7,047,000 | +5.0% | 89,533 | 0.0% | 0.07% | +1.5% |
| Q1 2014 | $6,714,000 | +21.4% | 89,533 | +24.9% | 0.06% | +16.1% |
| Q4 2013 | $5,532,000 | +11.3% | 71,664 | 0.0% | 0.06% | +1.8% |
| Q3 2013 | $4,970,000 | +10.1% | 71,664 | +2.7% | 0.06% | +3.8% |
| Q2 2013 | $4,515,000 | – | 69,784 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |